Rx Update: June 2000

Transition From Intravenous To Oral Therapy

Mary Ross, R.Ph., M.B.A.
Peer Review Status: Internally Reviewed


Converting patients from intravenous to oral therapy as soon as possible is advantageous and more convenient to the patient and nursing staff, as well as being more cost effective. Nurses, pharmacists and physicians can collaborate to identify potential candidates for conversion from intravenous to oral therapy, thereby providing patients with cost-effective alternatives when appropriate. Medications which have been targeted and reviewed by the Pharmacy and Therapeutics (P&T) Subcommittee for transition from intravenous to oral therapy include: ketorolac, fluconazole, H2 receptor antagonists (e.g., cimetidine and famotidine), acyclovir and antibiotics (e.g., ampicillin/sulbactam, azithromycin, cefazolin, ceftriaxone, erythromycin, levofloxacin, piperacillin/tazobactam, ticarcillin/clavulanate, and trimethoprim/sulfamethoxazole).

Rationale For Transition From IV To PO

Candidates For Conversion Conversion Not Recommended 1Formulary 1997; 32: 944-59
2Pharmacotherapy 1997; 2: 271-6

Title Page